Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
Reads0
Chats0
TLDR
The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.Abstract:
Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR 16 ) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD 17 ]) defined remission; a QIDS-SR 16 total score of ≥11 (HRSD 17 ≥14) defined relapse. Results: The QIDS-SR 16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, t...read more
Citations
More filters
Journal ArticleDOI
Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives.
TL;DR: The results lay the foundation for the biotechnological production of psilocybin in a controlled environment for pharmaceutical applications, and provide a starting point for the biosynthetic production of other tryptamine derivatives of therapeutic relevance.
Journal ArticleDOI
Physical activity and the prevention of depression: A cohort study.
Sunyoung Kim,Jae-Hyun Park,Mi Yeon Lee,Kang-Seob Oh,Dong-Won Shin,Young-Chul Shin,Young-Chul Shin +6 more
TL;DR: This study suggests an optimal amount of physical activity for reducing the onset of depressive symptoms, and maintaining an appropriate level ofPhysical activity for one year proved beneficial for decreasing incident depressive symptoms.
Journal ArticleDOI
Mental health and well-being in a 6-year follow-up of patients with depression: assessments of patients and clinicians.
Heli Koivumaa-Honkanen,Timo K. Tuovinen,Kirsi Honkalampi,Risto Antikainen,Jukka Hintikka,Kaisa Haatainen,Heimo Viinamäki +6 more
TL;DR: Depressive patients mainly attained a normal mood, adequate functional capacity and life satisfaction, and those with a slow recovery improved with successive treatment contacts, eventually reaching levels of mental health not significantly different from the others.
Journal ArticleDOI
Depression in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): The Mediating Role of Cognitive-Behavioral Factors.
TL;DR: Processes that are targeted in cognitive behavior therapy (CBT) for depression were associated with symptoms in adults with ADHD and such approaches could be further tailored to address the ADHD-depression comorbidity.
Journal ArticleDOI
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
Sudeepa Bhattacharyya,Ahmed T. Ahmed,Matthias Arnold,Duan Liu,Chunqiao Luo,Hongjie Zhu,Siamak MahmoudianDehkordi,Drew Neavin,Gregory Louie,Boadie W. Dunlop,Mark A. Frye,Liewei Wang,Richard M. Weinshilboum,Ranga R. Krishnan,A. John Rush,A. John Rush,A. John Rush,Rima Kaddurah-Daouk +17 more
TL;DR: Electrochemistry-based targeted metabolomics revealed changes in guanosine–homogentisic acid and methionine–tyrosine interactions associated with HRSD17, which suggest possible roles for the gut microbiome, oxidative stress, and inflammation-related mechanisms.
References
More filters
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
A. John Rush,Madhukar H. Trivedi,Hicham M. Ibrahim,Thomas J. Carmody,Bruce A. Arnow,Daniel N. Klein,John C. Markowitz,Philip T. Ninan,Susan G. Kornstein,Rachel Manber,Michael E. Thase,James H. Kocsis,Martin B. Keller +12 more
TL;DR: The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings.
Journal ArticleDOI
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project
Barbara Gandek,John E. Ware,Neil K. Aaronson,Giovanni Apolone,Jakob B. Bjorner,John Brazier,Monika Bullinger,Stein Kaasa,Alain Leplège,Luis Prieto,Marianne Sullivan +10 more
TL;DR: In this article, the authors compared the SF-12 and SF-36 summary measures in nine European countries (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom).
Journal ArticleDOI
Cumulative illness rating scale.
TL;DR: A Cumulative Illness Rating Scale, designed to meet the need for a brief, comprehensive and reliable instrument for assessing physical impairment, has been developed and tested and is well suited to a variety of research uses.
Journal ArticleDOI
The Inventory of Depressive Symptomatology (IDS): Psychometric properties.
TL;DR: Analysis of sensitivity to change in symptom severity in an open-label trial of fluoxetine showed that the IDs-C and IDS-SR were highly related to the 17-item Hamilton Rating Scale for Depression.